HBIO logo

HARVARD BIOSCIENCE INC

HBIONASDAQ
πŸ† #3423 by market capEarnings Aug 11 Β· PreUS Equity
$6.13β–Ό $0.27 (βˆ’4.37%)
Live
1hβ€”
24hβ–Ό 4.4%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$28M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-6.4%
Declining
πŸ“ŠGross Margin
58.4%
Healthy
πŸ’΅FCF Margin
8.0%
Moderate
βš–οΈP/S Ratio
0.3x
Cheap
Otter Score
54
Weak
No chart data available for HBIO.

Trading Snapshot

Day Range
$6.07 – $6.19
52-Week Range
$3.75 – $9.40
Volume
$2.23B
Avg Volume
$1.89B
Shares Outstanding
4.5M
Next Earnings
Sep 13, 2026

Fundamentals Snapshot

Annual Revenue
$87M
Last Q Revenue
$23M
P/E Ratio
β€”
P/S Ratio
0.3x
EPS (TTM)
$-2.20
Dividend Yield
β€”

Why Investors Own HBIO

  • βœ“High-growth profile β€” revenue up +47.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 50% gross margin and 28% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$87Mβ–² +45.8% YoY
Gross Margin (TTM)
49.8%β–² +3.5% YoY
Operating Income (TTM)
$29Mβ–² +45.8% YoY
Free Cash Flow (TTM)
$24Mβ–² +45.8% YoY

About HARVARD BIOSCIENCE INC

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
54/100

Analyst Price Target

β“˜
Average Target
$6.51
β–² +6.2% Upside
High Target$7.88
Low Target$5.21
Based on 32 analysts

Latest News & Updates